2021
Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia
Goshua G, Sinha P, Pischel L, Lee A, Cuker A. Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia. Blood 2021, 138: 751. DOI: 10.1182/blood-2021-144819.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioChronic immune thrombocytopeniaOne-way deterministic sensitivity analysisPost-splenectomy sepsisTPO-RATPO-RA therapyImmune thrombocytopeniaOverall response rateTreatment pathwaysProbabilistic sensitivity analysesDeterministic sensitivity analysesResponse rateAdverse eventsASH guidelinesStandard second-line treatment optionSecond-line treatment optionSecond-line treatment strategiesEarly useComplete response rateSecond-line therapySevere septic shockThrombopoietin receptor agonistsSeptic shock mortalityHealth system perspectiveCost of surgerySars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
Lee E, Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, Kruse A, Kessler C, Kruse C, Leavitt A, Lee A, Liebman H, Newland A, Ray A, Tarantino M, Thachil J, Kuter D, Cines D, Bussel J. Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood 2021, 138: 586. PMCID: PMC8701617, DOI: 10.1182/blood-2021-152918.Peer-Reviewed Original ResearchSARS-CoV-2 vaccinesITP exacerbationPre-vaccination baselineBristol-Myers SquibbImmune thrombocytopeniaPlatelet countRescue treatmentDose 2Dose 1Second dosePlatelet decreaseSpeakers bureauSpark TherapeuticsConsultancy feesFirst doseCSL BehringSupport associationsNovo NordiskSARS-CoV-2 vaccinationDiagnosis of ITPAdvisory CommitteeData Safety Monitoring BoardConcurrent autoimmune diseasesMore refractory diseasePrior medical treatment
2016
Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome
Wallace N, Dumont A, Burns A, Christopher T, Rinder H, Kriegel M, Buckley L, Erkan D, Lee A. Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. Blood 2016, 128: 4983. DOI: 10.1182/blood.v128.22.4983.4983.Peer-Reviewed Original ResearchLupus anticoagulant-hypoprothrombinemia syndromePartial thromboplastin timeAntiphospholipid syndromeImmune thrombocytopeniaAntiphospholipid antibodiesAPS patientsProthrombin timeCessation of anticoagulationGlycoprotein 1 antibodiesObstetrical antiphospholipid syndromeRole of thromboelastographySevere hemorrhagic complicationsSpecific coagulation defectsCatastrophic antiphospholipid syndromeChronic liver diseaseGlobal hemostasis assaysTraditional laboratory markersBaseline prolongationChronic aspirinPersistent positivityAdrenal hemorrhageAnticardiolipin antibodiesHemorrhagic complicationsImmunomodulatory treatmentAnticardiolipin IgG